Pharmacokinetic mismatch of tuberculosis drugs.
作者信息
Peloquin Charles A
出版信息
Antimicrob Agents Chemother. 2012 Mar;56(3):1666; author reply 1667. doi: 10.1128/AAC.06303-11.
Abstract
摘要
相似文献
1
Pharmacokinetic mismatch of tuberculosis drugs.抗结核药物的药代动力学不匹配
Antimicrob Agents Chemother. 2012 Mar;56(3):1666; author reply 1667. doi: 10.1128/AAC.06303-11.
2
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.药代动力学不匹配不会导致异烟肼或利福平耐药结核分枝杆菌的出现，而是会产生更好的抗菌效果：一种新的抗结核药物给药方案范例。
Antimicrob Agents Chemother. 2011 Nov;55(11):5085-9. doi: 10.1128/AAC.00269-11. Epub 2011 Sep 6.
3
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.耐多药结核病项目中高剂量利福平、异烟肼和吡嗪酰胺治疗的中敏剂量依赖性折点。
Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.
4
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.两例感染结核分枝杆菌的亚洲象（印度象）中异烟肼和利福平的药代动力学
J Zoo Wildl Med. 2016 Sep;47(3):868-871. doi: 10.1638/2015-0174.1.
5
Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.基于脂质体的抗结核药物疗法在豚鼠结核病模型中的应用
Int J Antimicrob Agents. 2004 Apr;23(4):414-5. doi: 10.1016/j.ijantimicag.2004.01.002.
6
7
Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.评估一种细胞内药代动力学体外感染模型作为评估结核病治疗工具的情况。
Int J Antimicrob Agents. 2007 Feb;29(2):212-6. doi: 10.1016/j.ijantimicag.2006.10.001. Epub 2007 Jan 3.
8
Effect of Genetic Variation of on Isoniazid and and on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.加纳儿童结核病患者中 基因变异对异烟肼和 及利福平药代动力学的影响。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02099-17. Print 2018 Mar.
9
[Advantages and disadvantages of longer and shorter chemotherapy regimens for multi-drug or rifampicin-resistant tuberculosis].[多药耐药或耐利福平结核病长疗程与短疗程化疗方案的优缺点]
Zhonghua Jie He He Hu Xi Za Zhi. 2019 May 12;42(5):333-338. doi: 10.3760/cma.j.issn.1001-0939.2019.05.005.
10
Acquisition of Rifampin Resistance in Pulmonary Tuberculosis.肺结核中利福平耐药性的获得
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02220-16. Print 2017 Apr.
引用本文的文献
1
TB and HIV Therapeutics: Pharmacology Research Priorities.结核病与艾滋病治疗：药理学研究重点
AIDS Res Treat. 2012;2012:874083. doi: 10.1155/2012/874083. Epub 2012 Jul 5.
本文引用的文献
1
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.药代动力学不匹配不会导致异烟肼或利福平耐药结核分枝杆菌的出现，而是会产生更好的抗菌效果：一种新的抗结核药物给药方案范例。
Antimicrob Agents Chemother. 2011 Nov;55(11):5085-9. doi: 10.1128/AAC.00269-11. Epub 2011 Sep 6.
2
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.利福布汀与洛匹那韦-利托那韦联合用药在HIV感染合并活动性结核病患者中的药代动力学评价
Clin Infect Dis. 2009 Nov 1;49(9):1305-11. doi: 10.1086/606056.
3
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.痰涂片阳性的肺结核患者中高剂量利福平的早期杀菌活性
Antimicrob Agents Chemother. 2007 Aug;51(8):2994-6. doi: 10.1128/AAC.01474-06. Epub 2007 May 21.
4
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.HIV 相关结核病每周两次治疗导致获得性利福平耐药。
Am J Respir Crit Care Med. 2006 Feb 1;173(3):350-6. doi: 10.1164/rccm.200503-417OC. Epub 2005 Aug 18.
5
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.HIV 合并结核病患者获得性利福霉素耐药性与利福布汀和异烟肼药代动力学之间的关联
Clin Infect Dis. 2005 May 15;40(10):1481-91. doi: 10.1086/429321. Epub 2005 Apr 14.
6
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.低异烟肼浓度与每周一次异烟肼和利福喷汀治疗结核病的结果
Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7. doi: 10.1164/rccm.200208-951OC. Epub 2003 Jan 16.
7
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.抗结核药物在最初14天内的杀菌和灭菌活性。
Am J Respir Crit Care Med. 2003 May 15;167(10):1348-54. doi: 10.1164/rccm.200210-1125OC. Epub 2003 Jan 6.
8
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.接受每周一次利福喷汀和异烟肼治疗的HIV相关结核病患者获得性利福霉素单耐药性。结核病试验联盟。
Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8.
9
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis.
Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):367-71. doi: 10.1164/arrd.1981.123.4.367.
Zotero 插件